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CASE REPORT
Late diagnosis of Fabry disease caused 
by a de novo mutation in a patient with end 
stage renal disease
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Abstract 
Background: We present the case of a white 35-year-old male with a diagnosis of Fabry disease and negative family 
history.
Case presentation: At the age of 31, he underwent a renal biopsy with a diagnosis of hypertension-induced 
nephroangiosclerosis. At the age of 35, he was referred to our hospital and started dialysis: the unusual finding of left 
ventricular hypertrophy with a normal ejection fraction and of myocardial fibrosis at the cardiac magnetic resonance 
suggested a diagnosis of Fabry disease, although there was no apparent family history—so extensive tests were 
subsequently undertaken. The patient had low plasma levels of α-galactosidase A and the genetic analysis showed a 
single nucleotide point mutation in hemizygosis at nucleotide c.901 C>T in exon 6 of the GLA gene, confirming the 
diagnosis of Fabry disease. We extended the genetic analysis to all family members of the patient (mother, sister and 
brothers) and none of them had any alteration in the GLA gene, suggesting a de novo mutation in the patient.
Conclusions: In a family, it is rare to find only one Fabry disease affected subject with a de novo mutation. These 
findings emphasize the importance of early diagnosis, genetic counseling and studying the genealogical tree of sus-
picious patients, even in absence of a typical family history.
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Background
Fabry disease (FD) (OMIM: 301500) is a rare X-linked 
hereditary disease (incidence 1:117.000 live births) 
caused by deficiency of the lysosomal alpha-galactosidase 
A enzyme (αGalA; E.C. 3.2.1.22) [1]. Human αGal A is 
a homodimeric glycoprotein with a molecular weight of 
46 kDa. GLA gene is located on Xq22.1, spans approxi-
mately 13 kb of genomic DNA and contains seven exons 
[2, 3]. As a consequence of the αGal A deficiency, neu-
tral glycosphingolipids, mainly globotriaosylceramide 
(Gb3), accumulate in a variety of cells and tissues, lead-
ing to a wide clinical spectrum of clinical manifestations 
[4]. Evolving knowledge suggests that FD has a wide 
spectrum of heterogeneous phenotypes, which ranges 
from the classical phenotype with kidney, cardiovascular 
and cerebrovascular disease [5], to a seemingly asympto-
matic disease, occasionally observed in females [6].
To date, over 600 mutations are described in the 
human gene mutation database (http://www.hgmd.org) 
as causative of FD. Moreover, most mutations are “pri-
vate”, occurring only in single pedigrees, while mutations 
at CpG dinucleotides have been identified in unrelated 
families [7]. Correlation between genotype and residual 
enzyme activity is not strong, depending on the mutation 
and additional genetic and non-genetic factors. Further-
more, very few “de novo” mutations have been detected 
with a frequency still unclear [8].
Here we report a case of non-diagnosed FD patient 
until the age of 35 without a familial history of the 
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disease; we performed both clinical and molecular diag-
nosis identifying a de novo mutation.
Case report
The patient, a white 35 years old man, had been healthy 
until the age of 31  years, except for mild articular pain 
and hypohidrosis since childhood. His father died of pul-
monary enphysema at the age of 54  years, and had no 
renal or cardiovascular disease. His mother, 60 years old, 
has hypertension and a past history of ischemic heart dis-
ease. The patient has two brothers aged 38 and 33 years 
and a sister aged 27 years, all perfectly healthy.
At the age of 31 years, he was hospitalized for protein-
uria in nephrotic range (6  g/24  h), hypertension and a 
reduced creatinine clearance rate (eGFR 57 mL/min). He 
underwent renal biopsy, with a diagnosis of nephroan-
giosclerosis. The biopsy material contained 20 glomeruli: 
global glomerular sclerosis, due to ischemic damage, was 
demonstrated in fourteen glomeruli, and the remaining 
six glomeruli showed only minor abnormalities; arte-
rial and arteriolar  hyalinosis were also present. Signs of 
tubular atrophy, interstitial fibrosis, and interlobular 
sclerosis were noted. Immunofluorescence examina-
tion did not show deposition of IgA, IgG, IgM, C1q, C3, 
k, and lambda fragments. Electron microscopy was not 
performed. At that time, the echocardiography showed 
concentric left ventricular hypertrophy (LVH) (ejection 
fraction 64 %) and an abdominal ultrasound showed no 
abnormalities. The patient was discharged with diagno-
sis of hypertension-induced nephroangiosclerosis and 
started treatment with ACE-inhibitors.
At the age of 35, because of the fast progression of renal 
disease and the need to start dialysis, the patient was 
referred to our hospital. On admission, his blood pres-
sure was 120/85  mm Hg, pulse was 72 beats/min and 
body temperature was 36 °C. Physical examination of the 
head, face, abdomen and extremities showed no abnor-
malities; moreover, there were no abnormal neurological 
findings.
Full blood count was normal. The values of blood bio-
chemical parameters were urea 210  mg/dL, creatinine 
9.4 mg/dL, total protein 8.0 g/dL and albumin 4.3 g/dL. 
Electrolytes and the result of liver function tests were 
normal. Twenty-four-hour protein excretion was 4.3  g, 
and his creatinine clearance was 9.3 mL/min. On admis-
sion, we also repeated abdominal ultrasound, which 
showed bilateral increased echogenicity, with a decrease 
in mean cortical thickness and loss of cortico-medullary 
definition. The echocardiography confirmed the concen-
tric LVH with a normal ejection fraction (63 %). Cardiac 
magnetic resonance imaging (MRI) was subsequently 
performed to better evaluate the cardiac involvement, 
that showed a prolonged myocardial T2 relaxation time 
at the level of the inferolateral wall, secondary to myocar-
dial fibrosis.
On the basis of these evidences and of a more accurate 
anamnesis, typical symptoms of FD—neuropathic pain, 
hypohidrosis, LVH, proteinuria and CKD—were identi-
fied, although there was no apparent family history of FD. 
Therefore, extensive tests were subsequently undertaken: 
evaluation of levels of α-Gal A in the plasma and molecu-
lar analysis were performed. Despite the finding of Malta 
crosses in the urine is a very common finding in Fabry 
disease, a urinalysis was not performed. The patient had 
low levels of α-Gal A (0.5  nmol 4  MU/mL/h; normal 
range 8–19 nmol 4 MU/mL/h); sequence analysis of the 
GLA gene (Fig. 1) showed a single nucleotide point muta-
tion in hemizygosis at nucleotide c.901 C>T in exon 6 
(p.Arg301X). We extended the genetic analysis to all fam-
ily members of the patient (mother, sister and brothers) 
and none of them had any alteration in the GLA gene, 
suggesting a de novo mutation in the patient.
Discussion
FD is an X-linked disease in which mutations of the GLA 
gene result in a deficiency of the enzyme α-galactosidase 
A and subsequent progressive, intralysosomal deposi-
tion of undegraded glycosphingolipid products, primar-
ily Gb3, in multiple organs [1, 2]. The initial signs and 
symptoms of FD emerge during childhood and adoles-
cence; however, because these signs and symptoms are 
not specific of FD, these patients are frequently misdiag-
nosed, and the correct diagnosis may be delayed. Major 
organ involvement typically occurs between the age of 20 
and 30 years and result in a significantly decreased qual-
ity of life for both heterozygous females and hemizygous 
males, with lifepan typically reduced by approximately 
15–20 years.
For the effective management of FD, an early diagnosis 
is required, and an early start of treatment remains essen-
tial in order to reduce the progression of the disease [2].
Due to its rarity and heterogeneity of the symptoms, 
FD clinical diagnosis remains a diagnostic challenge. In 
addition, the diagnosis is even more complex when fam-
ily history is absent.
Here, we report a case of late diagnosis of FD in a 
patient of 35  years with progressive renal disease. The 
late diagnosis is mostly due to the absence of family his-
tory and of ultrastructural analysis of the renal biopsy. 
However, the clinical history and the finding of the char-
acteristic cardiac abnormalities suggested the presence 
of FD, confirmed by the low α-Gal levels [3, 4] and the 
molecular analysis.
In fact, the molecular diagnosis, performed by 
sequencing the seven exons, the exon–intron boundaries 
and the promoter region of the GLA gene in the patient, 
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revealed in the patient the c.901 C>T (p.R301X) muta-
tion. This mutation, identified as a pathogenic mutation 
in 1995, inserts a stop codon in the aGalA protein and 
is reported to be responsible for the classical phenotype 
[5–9]. Moreover, it involves CpG dinucleotides, which 
are hot-spots for mutation [7].
The study of the relatives of the patient showed, sur-
prisingly, that none of his family members (mother, sis-
ter and brother) was affected by the disease; all of them 
showed normal enzymatic activity and the wild-type 
GLA gene. This indicated that the disease was caused by 
a de novo mutation, arisen spontaneously in this male 
patient. To confirm these findings, the analysis of the 
genetic profile of the patient and his relatives was carried 
out, proving that they had a family relationship.
To date, more than 600 mutations have been identified 
in human GLA gene that are responsible for FD, including 
missense and nonsense mutations, small and large dele-
tions (Human Gene Mutation Database, http://www.
hgmd.org). Such mutations are usually inherited and 
cases of de novo onset, i.e. arisen spontaneously, occur 
rarely [10]. De novo mutation may be due to maternal 
germline mosaicism or spontaneous mutation [8, 10] and 
are very difficult to diagnose. In the literature, only few 
cases of de novo mutations in FD have been described 
[8–11], for the difficulty to recognize them. In one, the 
mutation c.493 G>C in the third exon of the GLA gene 
was detected in a 44-year old male patient with classical 
clinical manifestations of the disease and negative fam-
ily history and in his 11-year old daughter [8]; another 
case described a patient with a de novo diagnosis of point 
mutation (R301X) in the GLA gene [9]. Other two studies 
described the cases of a 32-year old female and a 41-year 
old male, in which the de novo point mutation at position 
Fig. 1 Molecular characterization of the c.901 C>T mutation in GLA gene. Sequence analysis of GLA exon 6 in our patient. The top electrophero-
gram is from patient’s mother (a), the lower shows the patient’s mutation (b). The vertical bar indicates the position of the mutation
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691 of exon 5 and G373D, respectively, were detected [10, 
11].
Conclusions
Concluding, a strategy for timely FD diagnosis is recom-
mended and genetic testing would be performed in suspi-
cious patients even in absence of a typical family history 
to make an early diagnosis.
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